JAMES MATTHEWS: Open Payments
NPI 1669258711 · WASHINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,214 in 75 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $538 · 2025 $1,214
Food & beverage: $1,214
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $227 |
| Alkermes, Inc. | 10 | $197 |
| E.R. Squibb & Sons, L.L.C. | 10 | $170 |
| Teva Pharmaceuticals USA, Inc. | 10 | $154 |
| Neurocrine BioSciences, Inc. | 8 | $143 |
| Janssen Pharmaceuticals, Inc | 5 | $121 |
| Otsuka America Pharmaceutical, Inc. | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: VRAYLAR, ARISTADA, COBENFY, INGREZZA, INVEGA SUSTENNA, AUSTEDO XR, TRINTELLIX, REXULTI.
Industry payments across NC — which companies pay providers there.
